Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1906 1
1907 1
1910 1
1914 1
1918 1
1947 1
1952 1
1956 1
1961 1
1964 2
1965 1
1966 1
1967 3
1968 2
1969 4
1970 2
1971 3
1972 1
1974 3
1975 1
1976 2
1977 2
1978 2
1979 2
1980 2
1981 2
1982 1
1983 2
1985 1
1986 3
1987 2
1988 2
1989 5
1990 9
1991 6
1992 6
1993 5
1994 8
1995 8
1996 9
1997 5
1998 11
1999 7
2000 10
2001 8
2002 10
2003 13
2004 7
2005 16
2006 20
2007 24
2008 22
2009 22
2010 32
2011 31
2012 19
2013 18
2014 30
2015 24
2016 38
2017 35
2018 48
2019 40
2020 65
2021 80
2022 65
2023 56
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

815 results

Results by year

Filters applied: . Clear all
Page 1
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, Burgers J, Mahave M, Ahmed S, Schoenfeld AJ, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Gupta RG, Bushong J, Li L, Blum SI, Eccles LJ, Ramalingam SS. Brahmer JR, et al. Among authors: blum si. J Clin Oncol. 2023 Feb 20;41(6):1200-1212. doi: 10.1200/JCO.22.01503. Epub 2022 Oct 12. J Clin Oncol. 2023. PMID: 36223558 Free PMC article. Clinical Trial.
Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Cascone T, et al. Among authors: blum si. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. N Engl J Med. 2024. PMID: 38749033 Clinical Trial.
[Aplastic anemia].
Dewarrat N, Costanza M, Royer-Chardon C, Zermatten MG, De Leval L, Naveiras O, Blum S. Dewarrat N, et al. Among authors: blum s. Rev Med Suisse. 2024 Jun 26;20(880):1271-1275. doi: 10.53738/REVMED.2024.20.880.1271. Rev Med Suisse. 2024. PMID: 38938138 French.
Heavy metal.
Dewarrat N, Blum S. Dewarrat N, et al. Among authors: blum s. Blood. 2020 Oct 22;136(17):1993. doi: 10.1182/blood.2020007779. Blood. 2020. PMID: 33091139 Free article. No abstract available.
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.
Chalandon Y, Rousselot P, Chevret S, Cayuela JM, Kim R, Huguet F, Chevallier P, Graux C, Thiebaut-Bertrand A, Chantepie S, Thomas X, Vincent L, Berthon C, Hicheri Y, Raffoux E, Escoffre-Barbe M, Plantier I, Joris M, Turlure P, Pasquier F, Belhabri A, Guepin GR, Blum S, Gregor M, Lafage-Pochitaloff M, Quessada J, Lhéritier V, Clappier E, Boissel N, Dombret H. Chalandon Y, et al. Among authors: blum s. Blood. 2024 Jun 6;143(23):2363-2372. doi: 10.1182/blood.2023023502. Blood. 2024. PMID: 38452207 Clinical Trial.
Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, Passet M, Grardel N, Delabesse E, Kubetzko S, Caye-Eude A, Meyer C, Marschalek R, Lafage-Pochitaloff M, Thiebaut-Bertrand A, Balsat M, Escoffre-Barbe M, Blum S, Baumann M, Banos A, Straetmans N, Gallego-Hernanz MP, Chalandon Y, Graux C, Soulier J, Leguay T, Hunault M, Huguet F, Lhéritier V, Dombret H, Boissel N, Clappier E. Kim R, et al. Among authors: blum s. Blood. 2023 Nov 23;142(21):1806-1817. doi: 10.1182/blood.2023021501. Blood. 2023. PMID: 37595275 Free article.
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, Apolo AB, Choueiri TK. Cella D, et al. Among authors: blum si. Lancet Oncol. 2022 Feb;23(2):292-303. doi: 10.1016/S1470-2045(21)00693-8. Epub 2022 Jan 12. Lancet Oncol. 2022. PMID: 35032437 Free PMC article. Clinical Trial.
Infant Botulism, Israel, 2007-2021.
Goldberg B, Danino D, Levinsky Y, Levy I, Straussberg R, Dabaja-Younis H, Guri A, Almagor Y, Tasher D, Elad D, Baider Z, Blum S, Scheuerman O. Goldberg B, et al. Among authors: blum s. Emerg Infect Dis. 2023 Feb;29(2):235-241. doi: 10.3201/eid2902.220991. Emerg Infect Dis. 2023. PMID: 36692296 Free PMC article. Review.
815 results